OxSonics’ proprietary Sonosensitive Particles have been developed to carry pre-formed stabilised gas bubbles to enable sustained levels of inertial cavitation using low (quasi-diagnostic) ultrasound intensities at tumour sites.
The Particles possess in vivo circulation kinetics compatible with any therapeutic agent and sufficient time to administer ultrasound to the anatomic region of interest.
The Particles are designed to adopt the same administration route as the therapeutic agent, including intravenous (IV), intra-tumoural (IT) or intraperitoneal (IP).
The Particles are of a consistent size and have been designed to extravasate via the enlarged endothelial junction gaps exclusively found in solid tumours.
Due to the number density and physical properties of the Particles, the cavitation process is repeatable and sustained through successive ultrasound pulses. This enables gradual active convection of the therapeutic agent to distances of greater than 200 microns from blood vessels into tumours.
The particles are independently administered alongside the therapeutic agent, no drug reformulation is required.
The Particles are classified as medical devices not drugs, conferring a range of regulatory benefits.
The particles will be delivered to the patient via an infusion bag and giving set making their administration to the patient fit neatly within current oncology ward clinical practice.